已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

A simulation‐based comparison of estimation methods for adaptive and classical group sequential clinical trials

覆盖概率 置信区间 点估计 临时的 I类和II类错误 样本量测定 统计 标称水平 区间估计 区间(图论) 数学 中期分析 统计假设检验 算法 计算机科学 临床试验 医学 内科学 组合数学 历史 考古
作者
Bryan S Nelson,Lingyun Liu,Cyrus R. Mehta
出处
期刊:Pharmaceutical Statistics [Wiley]
卷期号:21 (3): 599-611 被引量:3
标识
DOI:10.1002/pst.2188
摘要

Statistical methods for controlling the type-I error of hypothesis tests in adaptive group sequential clinical trials are well established and well understood. However, methods for obtaining statistically valid point estimates and confidence intervals for adaptive designs are not as well established or as well understood. At the end of an adaptive trial, one may calculate the repeated confidence interval (RCI), which provides conservative coverage of δ , or the backward image confidence interval (BWCI), which provides exact coverage of δ and is an extension of the stagewise adjusted confidence interval (SWCI, used in classical group sequential designs). The BWCI can also provide a median unbiased estimate (MUE) of δ . There is a need to better understand the coverage and possible biases associated with these methods. We conducted a simulation study exploring parameter estimation following sample size reestimation based on testing methods with strong control of type-I error. Generally, the BWCI provided exact coverage, the naïve CI provided inconsistent coverage, and the RCI provided conservative coverage. Additionally, we note considerable asymmetry in the coverage from above/from below for the RCI, although we did not see any instance where the 95% RCI excluded the true parameter more than 2.5% on either side. At the end of an adaptive group sequential trial, we strongly recommend the use of the BWCI (and associated MUE), with the RCI computed during interim looks; the naïve CI should be avoided. These results and conclusions also hold true for classical group sequential designs.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ava应助cpl采纳,获得10
2秒前
幽默沛山完成签到 ,获得积分10
2秒前
2秒前
青屿发布了新的文献求助10
4秒前
5秒前
xiao_niu发布了新的文献求助10
5秒前
wzc发布了新的文献求助10
5秒前
6秒前
8秒前
11秒前
木木发布了新的文献求助10
11秒前
今后应助科研通管家采纳,获得10
11秒前
隐形曼青应助科研通管家采纳,获得10
12秒前
ccczzz应助科研通管家采纳,获得10
12秒前
12秒前
12秒前
Copyright应助科研通管家采纳,获得10
13秒前
13秒前
田様应助科研通管家采纳,获得10
13秒前
小蘑菇应助科研通管家采纳,获得10
13秒前
13秒前
14秒前
14秒前
麟语桐发布了新的文献求助10
14秒前
17秒前
17秒前
Coral完成签到,获得积分10
17秒前
张教授发布了新的文献求助10
19秒前
眼睛大若菱完成签到,获得积分10
20秒前
aroseisarose发布了新的文献求助10
20秒前
Wish发布了新的文献求助10
20秒前
24秒前
Laura_cxs完成签到 ,获得积分10
27秒前
深情安青应助青屿采纳,获得10
27秒前
wx完成签到 ,获得积分10
28秒前
文艺寄松完成签到 ,获得积分10
28秒前
29秒前
29秒前
FashionBoy应助瘦瘦以亦采纳,获得10
30秒前
刘Boyce完成签到,获得积分10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
Elgar Concise Encyclopedia of Space Law 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6944221
求助须知:如何正确求助?哪些是违规求助? 8629728
关于积分的说明 18305354
捐赠科研通 6379282
什么是DOI,文献DOI怎么找? 3079195
关于科研通互助平台的介绍 2120003
邀请新用户注册赠送积分活动 2056076